AQST Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
13.8M
-4.3%
14.4M
+11.0%
13.0M
+1.6%
12.8M
+28.0%
10.0M
Cost of Revenue
4.0M
+15.8%
3.5M
-40.6%
5.8M
+29.5%
4.5M
-1.2%
4.6M
Gross Profit
9.8M
-10.7%
11.0M
+52.9%
7.2M
-13.5%
8.3M
+52.5%
5.4M
Operating Expenses
18.0M
+18.7%
15.2M
-59.5%
37.5M
+76.5%
21.2M
+26.2%
16.8M
R&D
4.0M
-5.8%
4.2M
+31.5%
3.2M
-29.4%
4.5M
+10.4%
4.1M
SG&A
14.1M
+28.1%
11.0M
-66.6%
32.8M
+115.2%
15.3M
+20.0%
12.7M
Operating Income
-8223000
-95.6%
-4204000
+86.1%
-30272000
-134.4%
-12912000
-13.6%
-11368000
EBITDA
-8087000
-97.7%
-4091000
+86.4%
-30142000
-136.0%
-12773000
-13.8%
-11228000
Net Income
-22864000
-183.8%
-8057000
+74.7%
-31860000
-106.3%
-15446000
-14.0%
-13548000
EPS (Basic)
$-0.18
-157.1%
$-0.07
+73.1%
$-0.26
-85.7%
$-0.14
+0.0%
$-0.14
EPS (Diluted)
$-0.18
-157.1%
$-0.07
+73.1%
$-0.26
-85.7%
$-0.14
+0.0%
$-0.14
Shares (Diluted)
125.0M
+1.9%
122.6M
+0.3%
122.3M
+10.6%
110.6M
+11.3%
99.3M
Aquestive Therapeutics (AQST) โ€” Financials